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Background
Systemic lupus erythematosus (SLE) is a systemic auto-
immune disorder that commonly affects the heart, resulting
in a 7 to 9 times greater incidence of cardiovascular disease
(CVD) in SLE patients compared to healthy controls.
Female patients with SLE between 35 and 44 years old have
an incidence of myocardial infarction over 50 times greater
than that observed in the Framingham cohort. Diffuse
myocardial fibrosis can be detected non-invasively by extra-
cellular volume (ECV) mapping based on pre- and postcon-
trast T1 measurements using cardiovascular magnetic
resonance (CMR). We aimed to detect subclinical diffuse
myocardial fibrosis in SLE using CMR T1 mapping.
Methods
23 SLE patients (22 female, mean age 41 ± 9 years) and
23 matched controls (22 female, mean age 42 ± 9 years)
without previously known cardiovascular disease under-
went CMR at 1.5T. CMR evaluation included late gadoli-
nium enhancement (LGE) [IV gadoterate meglumine at
0.15 mmol/kg], T1 mapping pre- and postcontrast, cine,
tagging, and T2-weighted imaging.
Results
Regional fibrosis on LGE imaging was found in 5 SLE
patients (22%) compared to none of controls. Presence
of diffuse myocardial fibrosis in SLE was confirmed by
significantly higher precontrast T1 values (981 ± 31
vs. 960 ± 21 ms, p = 0.010), decreased postcontrast
T1 values (445 ± 31 vs. 470 ± 24 ms, p = 0.005) and
expansion of ECV (31.8 ± 4.1 vs. 28.9 ± 2.0 %, p = 0.004).
Diffuse myocardial fibrosis was evident in SLE regardless
of the presence of any regional fibrosis. Left ventricular
volumes, mass and ejection fraction were similar between
SLE patients and controls. However, peak systolic cir-
cumferential strain (-17.0 ± 1.6 vs. -19.3 ± 1.1, p < 0.001)
and peak diastolic strain rate (79 ± 26 vs. 119 ± 15 s-1,
p < 0.001) were impaired in SLE. Presence of diastolic
dysfunction is SLE was further supported by larger left
atrial diameters (31 ± 5 vs. 26 ± 4 mm, p < 0.001).
Abnormal myocardial systolic strain and diastolic strain
rate correlated with diffuse myocardial fibrosis indices.
There was no evidence of myocardial edema in SLE.
Conclusions
Cardiac involvement is common in SLE patients with no
cardiovascular symptoms, and includes both focal and
diffuse myocardial fibrosis, which is associated with
impaired systolic and diastolic strain parameters. CMR
is a robust non-invasive tool for the assessment of diffuse
myocardial fibrosis and subclinical cardiac involvement
in inflammatory heart disease.
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Female sex, n (%) 22 (92) 22 (92) 1.00
Age, years 42 ± 9 41 ± 9 0.68
Current smokers, n (%) 1 (4) 3 (13) 0.10
Hypertension, n (%) 0 0 -
Diabetes, n (%) 0 0 -
Hyperlipidaemia, n (%) 1 (4) 0 -
BMI, kg/m2 23 ± 3 28 ± 6 < 0.001
SLEDAI (median, IQR) N/A 9 (7-14) -
ESR, mm/hr (median, IQR) N/A 6 (4-9) -
CRP, mg/L (median, IQR) 1 (0-1) 3 (2-6) < 0.001
Hemoglobin, g/L 13 ± 1 12 ± 1 0.37
Duration of SLE, years (median, IRQ) N/A 9 (6-14) -
Duration of DMARDs, years (median, IQR) N/A 7 (4-10) -
LVEDV indexed to BSA, ml/m2 79 ± 15 78 ± 13 0.91
LVESV indexed to BSA, ml/m2 21 ± 5 20 ± 6 0.43
LVEF, % 74 ± 5 72 ± 5 0.17
LV Mass indexed to BSA, g/m2 49 ± 10 46 ± 11 0.21
LA size, mm 26 ± 4 31 ± 5 < 0.001
Mid SA circumferential strain -19.3 ± 1.1 -17.0 ± 1.6 < 0.001
Peak diastolic circumferential strain rate (s-1) 119 ± 15 79 ± 26 < 0.001
Presence of LGE (%) 0 5 (22) -
Volume fraction of LGE > 2SD (%) STIR T2 Ratio 0 2.6 ± 0.2 -
STIR T2 Ratio 1.5 ± 0.1 1.6 ± 0.1 0.06
Continuous data are mean ± SD unless otherwise indicated. BMI, body mass index; CRP, C-reactive protein; DMARD, disease modifying anti-rheumatic drug; ESR,
erythrocyte sedimentation rate; IQR, interquartile range; LA, left atrium; LGE, late gadolinium enhancement; LV, left ventricle/ventricular; LVEDV, left ventricular
end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; SA, short axis; SLEDAI, systemic lupus erythematosus
disease activity index; SLE, systemic lupus erythematosus; STIR, short Tau inversion recovery
Figure 1
Ntusi et al. Journal of Cardiovascular Magnetic
Resonance 2014, 16(Suppl 1):P307
http://www.jcmr-online.com/content/16/S1/P307
Page 2 of 2
